scholarly journals 117: Association Between Fraction of Exhaled Nitrous Oxide (FeNO), Parameters of Asthma Control and Inhaled Corticosteroid Type in a Regional Paediatric Asthma Center

2014 ◽  
Vol 19 (6) ◽  
pp. e76-e77
Author(s):  
RW Smith ◽  
K Downey ◽  
N Snow ◽  
S Dell ◽  
W Smith
Keyword(s):  
Nitrous Oxide ◽  
Asthma Control ◽  
Inhaled Corticosteroid ◽  
Paediatric Asthma

Introduction of a new paediatric asthma guideline: Effects on asthma control levels

2017 ◽  
Vol 28 (3) ◽  
pp. 266-272 ◽  
Author(s):  
S. C. Hammer ◽  
L. J. H. Sonneveld ◽  
K. D. G. van de Kant ◽  
H. J. Hendriks ◽  
J. W. Heynens ◽  
...  
Keyword(s):  
Asthma Control ◽  
Paediatric Asthma ◽  
Asthma Guideline

scholarly journals First analysis of the Severe Paediatric Asthma Collaborative in Europe registry

2020 ◽  
Vol 6 (4) ◽  
pp. 00566-2020
Author(s):  
Norrice M. Liu ◽  
Karin C.L. Carlsen ◽  
Steve Cunningham ◽  
Grazia Fenu ◽  
Louise J. Fleming ◽  
...  
Keyword(s):  
Asthma Control ◽  
Severe Asthma ◽  
Suboptimal Control ◽  
High Dose ◽  
Asthma Control Test ◽  
European Respiratory Society ◽  
Paediatric Asthma ◽  
Global Initiative For Asthma ◽  
Global Initiative ◽  
Long Acting

New biologics are being continually developed for paediatric asthma, but it is unclear whether there are sufficient numbers of children in Europe with severe asthma and poor control to recruit to trials needed for registration. To address these questions, the European Respiratory Society funded the Severe Paediatric Asthma Collaborative in Europe (SPACE), a severe asthma registry. We report the first analysis of the SPACE registry, which includes data from 10 paediatric respiratory centres across Europe.Data from 80 children with a clinical diagnosis of severe asthma who were receiving both high-dose inhaled corticosteroid and long-acting β2-agonist were entered into the registry between January 2019 and January 2020. Suboptimal control was defined by either asthma control test, or Global Initiative for Asthma criteria, or ≥2 severe exacerbations in the previous 12 months, or a combination.Overall, 62 out of 80 (77%) children had suboptimal asthma control, of whom 29 were not prescribed a biologic. However, in 24 there was an option for starting a licensed biologic. 33 children with suboptimal control were prescribed a biologic (omalizumab (n=24), or mepolizumab (n=7), or dupilumab (n=2)), and for 29 there was an option to switch to a different biologic.We conclude that the SPACE registry provides data that will support the planning of studies of asthma biologics. Not all children on biologics achieve good asthma control, and there is need for new trial designs addressing biologic switching.

Lessons learned from clinical trials of asthma

2019 ◽  
Vol 40 (6) ◽  
pp. 410-413
Author(s):  
Paul A. Greenberger
Keyword(s):  
Asthma Control ◽  
Severe Asthma ◽  
Immunoglobulin E ◽  
Environmental Control ◽  
Mild Asthma ◽  
Inhaled Corticosteroid ◽  
Biologic Therapies ◽  
Asthma Control Questionnaire ◽  
Exacerbation Rate ◽  
Sputum Eosinophilia

Exacerbations of persistent or intermittent asthma should be anticipated by physicians and health-care professionals. Patients who are likely to experience an exacerbation often have a history of an exacerbation in the previous year, and the absolute eosinophil count in peripheral blood is ≥ 400/μL. Similarly, expectorated or induced sputum eosinophilia of ≥2% is associated with exacerbations. These phenotypic findings have led to effective biologic therapies, which target eosinophils or immunoglobulin E or the T-helper type 2 phenotype, especially in children, adolescents, and adults with frequent exacerbations. In children, a reduced forced expiratory volume in the first second of expiration (FEV1) to forced vital capacity ratio can be associated with future exacerbations, although the FEV1 may be in the normal range, even with children who have persistent severe asthma. Asthma control questionnaires did not differentiate between children with or children without a future exacerbation. Alternatively, in adults, the lower baseline FEV1 (2.3 L [74% predicted] versus 2.5 L [78% predicted]) identified patients more likely to have a future exacerbation compared with patients who were not having an exacerbation. After correcting for FEV1, the asthma control questionnaire data were associated with exacerbations. In adolescents (ages ≥ 12 years) and adults with persistent mild asthma, most (73%) did not have sputum eosinophilia, and some of these patients responded well to the anticholinergic, tiotropium, which would argue differently from administration of an inhaled corticosteroid as first-line controller therapy. In a three-track study of patients with persistent mild asthma, as-needed budesonide-formoterol and scheduled budesonide were associated with approximately one-half of the annual exacerbation rate of as-needed albuterol. In patients with persistent moderate-to-severe asthma, tiotropium added to controller therapy caused an increase in FEV1 without improving the asthma control questionnaire findings. There were two studies that explored whether either quadrupling or quintupling the inhaled corticosteroid at the first sign of loss of control of asthma would provide meaningful reductions of severe exacerbations of asthma, but the findings did not support this strategy. Both biologic therapies and environmental control (dust mite impermeable encasings) have resulted in reductions of exacerbations in patients with persistent moderate and severe asthma.

scholarly journals Expression of SMARCD1 interacts with age in association with asthma control on inhaled corticosteroid therapy

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Michael J. McGeachie ◽  
Joanne E. Sordillo ◽  
Amber Dahlin ◽  
Alberta L. Wang ◽  
Sharon M. Lutz ◽  
...  
Keyword(s):  
Asthma Control ◽  
Corticosteroid Therapy ◽  
Inhaled Corticosteroid

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

2000 ◽  
Vol 106 (6) ◽  
pp. 1088-1095 ◽  
Author(s):  
Harold S. Nelson ◽  
William W. Busse ◽  
Edward Kerwin ◽  
Nina Church ◽  
Amanda Emmett ◽  
...  
Keyword(s):  
Fluticasone Propionate ◽  
Asthma Control ◽  
Low Dose ◽  
Inhaled Corticosteroid

scholarly journals Pragmatic evaluation of inhaled corticosteroid particle size formulations on asthma control

2019 ◽  
Vol 49 (10) ◽  
pp. 1321-1327 ◽  
Author(s):  
Chris RuiWen Kuo ◽  
Sunny Jabbal ◽  
William Anderson ◽  
Brian J. Lipworth
Keyword(s):  
Particle Size ◽  
Asthma Control ◽  
Inhaled Corticosteroid

Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11

2008 ◽  
Vol 2 (3) ◽  
pp. 149-157 ◽  
Author(s):  
Hans Jürgen Hoffmann ◽  
Lars Peter Nielsen ◽  
Henrik Harving ◽  
John H. Heinig ◽  
Ronald Dahl
Keyword(s):  
Asthma Control ◽  
Corticosteroid Treatment ◽  
Inhaled Corticosteroid ◽  
Step Down ◽  
Low Serum
Sign in / Sign up

Export Citation Format

Share Document